Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
- 378 Downloads
Correction to: Journal of Neurology https://doi.org/10.1007/s00415-018-8812-0
In the original article, the co-author’s family name has been published incorrectly. The correct family name should be Constantinescu.
Compliance with ethical standards
This study has been approved by the local institutional review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- 1.Genzyme (2016) Lemtrada [prescribing information]. Genzyme Corporation, CambridgeGoogle Scholar
- 2.Cohen JA, Coles AJ, Arnold DL et al (2012) CARE MS I Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3 CrossRefPubMedGoogle Scholar
- 8.Sylvan ES, Lundin J, Ipek M et al (2014) Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol 83:1725–1733. https://doi.org/10.1007/s00277-014-2105-1 CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.